Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.

Kvarnhammar AM, Veitonmäki N, Hägerbrand K, Dahlman A, Smith KE, Fritzell S, von Schantz L, Thagesson M, Werchau D, Smedenfors K, Johansson M, Rosén A, Åberg I, Winnerstam M, Nyblom E, Barchan K, Furebring C, Norlén P, Ellmark P.

J Immunother Cancer. 2019 Apr 11;7(1):103. doi: 10.1186/s40425-019-0570-8.

2.

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies.

Irenaeus SMM, Nielsen D, Ellmark P, Yachnin J, Deronic A, Nilsson A, Norlén P, Veitonmäki N, Wennersten CS, Ullenhag GJ.

Int J Cancer. 2019 Sep 1;145(5):1189-1199. doi: 10.1002/ijc.32141. Epub 2019 Mar 8.

PMID:
30664811
3.

Bispecific antibodies in cancer immunotherapy.

Dahlén E, Veitonmäki N, Norlén P.

Ther Adv Vaccines Immunother. 2018 Feb;6(1):3-17. doi: 10.1177/2515135518763280. Epub 2018 Mar 28. Review.

4.

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.

Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH, Ellmark P.

Clin Cancer Res. 2015 Mar 1;21(5):1115-26. doi: 10.1158/1078-0432.CCR-14-0913. Epub 2014 Oct 14.

5.

A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.

Veitonmäki N, Hansson M, Zhan F, Sundberg A, Löfstedt T, Ljungars A, Li ZC, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, Mårtensson L, Teige I, Tricot G, Frendéus B.

Cancer Cell. 2013 Apr 15;23(4):502-15. doi: 10.1016/j.ccr.2013.02.026.

6.

Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells.

Ernkvist M, Birot O, Sinha I, Veitonmaki N, Nyström S, Aase K, Holmgren L.

Biochim Biophys Acta. 2008 Mar;1783(3):429-37. doi: 10.1016/j.bbamcr.2007.11.018. Epub 2007 Dec 8.

7.

Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo.

Levchenko T, Veitonmäki N, Lundkvist A, Gerhardt H, Ming Y, Berggren K, Kvanta A, Carlsson R, Holmgren L.

FASEB J. 2008 Mar;22(3):880-9. Epub 2007 Nov 5.

PMID:
17984175
8.

A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth.

Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9208-13. Epub 2006 Jun 5.

9.

p130-angiomotin associates to actin and controls endothelial cell shape.

Ernkvist M, Aase K, Ukomadu C, Wohlschlegel J, Blackman R, Veitonmäki N, Bratt A, Dutta A, Holmgren L.

FEBS J. 2006 May;273(9):2000-11.

10.

Gene transfer of kringle 1-5 suppresses tumor development and improves prognosis of mice with hepatocellular carcinoma.

Torimura T, Ueno T, Kin M, Taniguchi E, Nakamura T, Inoue K, Sakata R, Hashimoto O, Sakamoto M, Ohira H, Kumashiro R, Sata M, Yano H, Kojiro M, Veitonmaki N, Cao Y.

Gastroenterology. 2006 Apr;130(4):1301-10.

PMID:
16618420
11.

Angiomotin regulates endothelial cell-cell junctions and cell motility.

Bratt A, Birot O, Sinha I, Veitonmäki N, Aase K, Ernkvist M, Holmgren L.

J Biol Chem. 2005 Oct 14;280(41):34859-69. Epub 2005 Jul 25.

12.

Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis.

Veitonmäki N, Cao R, Wu LH, Moser TL, Li B, Pizzo SV, Zhivotovsky B, Cao Y.

Cancer Res. 2004 May 15;64(10):3679-86.

13.

Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y.

Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81.

14.

Kringle structures and antiangiogenesis.

Cao Y, Cao R, Veitonmäki N.

Curr Med Chem Anticancer Agents. 2002 Nov;2(6):667-81. Review.

PMID:
12678719
15.

Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A/pRb.

Veitonmäki N, Fuxe J, Hultdin M, Roos G, Pettersson RF, Cao Y.

FASEB J. 2003 Apr;17(6):764-6. Epub 2003 Feb 5.

PMID:
12586745
16.

Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients.

Cao Y, Veitonmaki N, Keough K, Cheng H, Lee LS, Zurakowski D.

Int J Mol Med. 2000 May;5(5):547-51.

PMID:
10762660
17.

Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis.

Cao R, Wu HL, Veitonmäki N, Linden P, Farnebo J, Shi GY, Cao Y.

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5728-33.

Supplemental Content

Loading ...
Support Center